BMY240802C46000
- 3.40
- -1.11-24.61%
Bristol-Myers Squibb Newsroom
Leerink Partners Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $53
Bristol-Myers Squibb: A Hold Rating Amidst Short-Term Gains and Long-Term Pricing Concerns
Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ
USA pharmaceutical stocks 'switching trading': two weight-loss giants fall, while stagnant giants rise in turn.
The rotation of this stock price is not only due to momentum effects, but also because the USA pharmaceutical industry seems to have responded well to the regulatory pressure brought by the Inflation Reduction Act.
Bristol-Myers Squibb Options Spot-On: On July 29th, 84,323 Contracts Were Traded, With 861.54K Open Interest
Barclays Cuts Bristol Myers to Underweight, Cites Recent Run up
Bristol-Myers Stock Snaps Six Days of Gains
Is Bristol-Myers Squibb's Stock Rally Justified? Bull Vs. Bear Analysts On Q2 Earnings
Bristol-Myers Squibb on Track for Longest Winning Streak Since April 2021 -- Data Talk
Wolfe Adjusts Price Target on Bristol-Myers Squibb to $57 From $55, Maintains Outperform Rating
BofA Securities Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $55
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields
This Bristol-Myers Squibb Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
Morgan Stanley Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Maintains Target Price $37
Morgan Stanley Reaffirms Their Sell Rating on Bristol-Myers Squibb (BMY)
Bristol-Myers Squibb Cut to Underweight From Equal-Weight by Barclays
Bristol-Myers Squibb Price Target Maintained With a $41.00/Share by Barclays
Bristol-Myers Squibb Analyst Ratings
Today's Morning Movers and Top Ratings: TSLA, DIS, ABT, COIN and More
Truist Financial Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $62